Hanmi Pharm seeking regulatory approval for new combination formulation of irbesartan and atorvastat

Published: 2013-06-14 06:58:00

Updated: 2013-06-14 06:58:00

Hanmi Pharmaceutical said Wednesday that it has filed a new drug application for its combination formulation containing irbesartan and atorvastatin to obtain the market authorization from to the Ministry of Food and Drug Safety (MFDS).

On May 15, Hanmi completed its Phase III trials in 22 loca...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK